Alnylam Pharmaceuticals, Inc. (ALNY) Rating Reiterated by Ladenburg Thalmann Financial Services
Ladenburg Thalmann Financial Services restated their buy rating on shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in a report released on Thursday morning. The brokerage currently has a $146.00 price objective on the biopharmaceutical company’s stock, up from their previous price objective of $90.00.
ALNY has been the topic of several other research reports. Needham & Company LLC restated a buy rating and set a $85.00 target price (down previously from $98.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. Chardan Capital restated a buy rating on shares of Alnylam Pharmaceuticals in a report on Monday, September 11th. Nomura started coverage on Alnylam Pharmaceuticals in a report on Thursday, September 14th. They set a reduce rating and a $56.00 target price on the stock. ValuEngine upgraded Alnylam Pharmaceuticals from a strong sell rating to a sell rating in a report on Friday, June 2nd. Finally, Instinet started coverage on Alnylam Pharmaceuticals in a report on Friday, September 15th. They set a reduce rating and a $56.00 target price on the stock. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average price target of $93.11.
Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 113.80 on Thursday. Alnylam Pharmaceuticals has a 12-month low of $31.38 and a 12-month high of $118.40. The firm’s market cap is $10.44 billion. The company has a 50-day moving average of $81.14 and a 200 day moving average of $69.12.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.22) by ($0.12). The company had revenue of $15.93 million for the quarter, compared to analyst estimates of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The business’s revenue was up 82.9% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.05) earnings per share. Equities analysts predict that Alnylam Pharmaceuticals will post ($5.19) EPS for the current year.
In other Alnylam Pharmaceuticals news, President Barry E. Greene sold 76,815 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The stock was sold at an average price of $100.00, for a total transaction of $7,681,500.00. Following the transaction, the president now owns 165,399 shares in the company, valued at $16,539,900. The sale was disclosed in a document filed with the SEC, which is available through this link. 4.30% of the stock is currently owned by company insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $148,000. QS Investors LLC raised its position in shares of Alnylam Pharmaceuticals by 59.7% during the second quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock worth $192,000 after purchasing an additional 900 shares during the period. Westpac Banking Corp acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $202,000. The Manufacturers Life Insurance Company raised its position in shares of Alnylam Pharmaceuticals by 7.0% during the second quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock worth $203,000 after purchasing an additional 167 shares during the period. Finally, Prudential Financial Inc. acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth about $215,000. 94.25% of the stock is currently owned by institutional investors.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.